Journal
SCIENTIFIC REPORTS
Volume 7, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-14986-6
Keywords
-
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
- British Heart Foundation [PG/13/88/30556]
- Drugs for Neglected Diseases initiative (DNDi)
- EU Marie Curie Fellowship
- UK BBSRC LiDO PhD studentship
- UK MRC [MR/K000551/1, MR/M01360X/1, MR/N010469/1]
- Faculty baseline funding [BAS/1/1020-01-01]
- Biotechnology and Biological Sciences Research Council [1351999] Funding Source: researchfish
- British Heart Foundation [PG/13/88/30556] Funding Source: researchfish
- Medical Research Council [MC_PC_15103, MR/M01360X/1, MR/N010469/1] Funding Source: researchfish
- MRC [MR/M01360X/1, MR/N010469/1, MR/K000551/1, MC_PC_15103] Funding Source: UKRI
Ask authors/readers for more resources
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects 5-8 million people in Latin America. Although the nitroheterocyclic compound benznidazole has been the front-line drug for several decades, treatment failures are common. Benznidazole is a pro-drug and is bio-activated within the parasite by the mitochondrial nitroreductase TcNTR-1, leading to the generation of reactive metabolites that have trypanocidal activity. To better assess drug action and resistance, we sequenced the genomes of T. cruzi Y strain (35.5 Mb) and three benznidazole-resistant clones derived from a single drug-selected population. This revealed the genome-wide accumulation of mutations in the resistant parasites, in addition to variations in DNA copy-number. We observed mutations in DNA repair genes, linked with increased susceptibility to DNA alkylating and inter-strand cross-linking agents. Stop-codon-generating mutations in TcNTR-1 were associated with cross-resistance to other nitroheterocyclic drugs. Unexpectedly, the clones were also highly resistant to the ergosterol biosynthesis inhibitor posaconazole, a drug proposed for use against T. cruzi infections, in combination with benznidazole. Our findings therefore identify the highly mutagenic activity of benznidazole metabolites in T. cruzi, demonstrate that this can result in multi-drug resistance, and indicate that vigilance will be required if benznidazole is used in combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available